Merck ’s Novel HIF-2α Inhibitor Showed an Objective Response Rate of Nearly 30% in Patients with von Hippel-Lindau (VHL) Disease-Associated Clear Cell Renal Cell Carcinoma

KENILWORTH, N.J.--(BUSINESS WIRE) May 13, 2020 --Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced first-time results from a Phase 2 trial evaluating the hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials